M&A Deal Summary

Pfizer Acquires Pharmacia

On April 16, 2003, Pfizer acquired life science company Pharmacia for 60.0B USD

Acquisition Highlights
  • This is Pfizer’s 2nd transaction in the Life Science sector.
  • This is Pfizer’s 3rd largest (disclosed) transaction.
  • This is Pfizer’s 2nd transaction in the United States.
  • This is Pfizer’s 2nd transaction in New Jersey.

M&A Deal Summary
Date 2003-04-16
Target Pharmacia
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 60.0B USD

Target

Pharmacia

Peapack, New Jersey, United States
Pharmacia Corp. a pharmaceutical and biotechnological company.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 2 of 43
Sector (Life Science) 2 of 39
Type (Add-on Acquisition) 1 of 31
State (New Jersey) 2 of 3
Country (United States) 2 of 31
Year (2003) 1 of 2
Size (of disclosed) 3 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2002-12-17 Cadbury Adams USA

Parsippany, New Jersey, United States

Cadbury Adams is a provider of confectionery products. Adams does business in over 70 countries.

Sell $4.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2003-11-25 Pfizer s New Drug Application

United States

Pfizer's New Drug Application (NDA) for Cardura(R) XL, a sustained-release formulation of doxazosin mesylate, used to treat benign prostatic hyperplasia (BPH).

Sell $35M
Mergr

Product

Company

Legal